Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Zelira Therapeutics ( (AU:ZLD) ) just unveiled an update.
Zelira Therapeutics Limited announced a change in the interest of its director, Osagie Imasogie, due to the lapse of 335,094 Class B performance rights as conditions were not met. This update is significant as it reflects the director’s current holdings and could impact the company’s stock market perception and investor relations, pointing to potential strategic adjustments or operational emphasis within the company.
More about Zelira Therapeutics
Zelira Therapeutics Limited operates within the biopharmaceutical industry, specializing in the development and commercialization of cannabinoid-based medicines. The company’s primary products target the treatment of various medical conditions, with a strong focus on leveraging cannabinoid compounds for therapeutic benefits.
YTD Price Performance: 2.86%
Average Trading Volume: 443
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $4.44M
For detailed information about ZLD stock, go to TipRanks’ Stock Analysis page.
